These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 33013894)

  • 1.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
    Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
    J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
    J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
    Sánchez Acosta G; Kinaciyan T; Kitzmüller C; Möbs C; Pfützner W; Bohle B
    J Allergy Clin Immunol; 2020 Oct; 146(4):894-900.e2. PubMed ID: 32259540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.
    Gadermaier E; Marth K; Lupinek C; Campana R; Hofer G; Blatt K; Smiljkovic D; Roder U; Focke-Tejkl M; Vrtala S; Keller W; Valent P; Valenta R; Flicker S
    Allergy; 2018 Jul; 73(7):1425-1435. PubMed ID: 29315611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules.
    Pree I; Shamji MH; Kimber I; Valenta R; Durham SR; Niederberger V
    Clin Exp Allergy; 2010 Sep; 40(9):1346-52. PubMed ID: 20604801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
    Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1.
    Svenson M; Jacobi HH; Bødtger U; Poulsen LK; Rieneck K; Bendtzen K
    Mol Immunol; 2003 Jan; 39(10):603-12. PubMed ID: 12431394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural human Bet v 1-specific IgG antibodies recognize non-conformational epitopes whereas IgE reacts with conformational epitopes.
    Brazhnikov G; Smolnikov E; Litovkina A; Jiang T; Shatilov A; Tulaeva I; Tulaev M; Karaulov A; Poroshina A; Zhernov Y; Focke-Tejkl M; Weber M; Akinfenwa O; Elisyutina O; Andreev S; Shilovskiy I; Shershakova N; Smirnov V; Fedenko E; Lepeshkova TS; Beltyukov EC; Naumova VV; Kundi M; Khaitov M; Wiedermann U; Valenta R; Campana R
    Allergy; 2023 Dec; 78(12):3136-3153. PubMed ID: 37701941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgE mimotopes of birch pollen allergen Bet v 1 induce blocking IgG in mice.
    Ganglberger E; Grünberger K; Wiedermann U; Vermes M; Sponer B; Breiteneder H; Scheiner O; Boltz G; Jensen-Jarolim E
    Int Arch Allergy Immunol; 2001; 124(1-3):395-7. PubMed ID: 11307026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction.
    Eibensteiner P; Denépoux S; Steinberger P; Kraft D; Visco V; Banchereau J; Lebecque S; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):190-2. PubMed ID: 10224374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral allergy syndrome.
    Guhsl EE; Hofstetter G; Lengger N; Hemmer W; Ebner C; Fröschl R; Bublin M; Lupinek C; Breiteneder H; Radauer C
    Allergy; 2015 Jan; 70(1):59-66. PubMed ID: 25327982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.
    Selb R; Eckl-Dorna J; Vrtala S; Valenta R; Niederberger V
    Allergy; 2013 Sep; 68(9):1199-202. PubMed ID: 23998344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.